糖尿病網膜症の市場規模、シェア、成長分析、タイプ別、治療法別、診断別、投与経路別、エンドユーザー別、流通チャネル別、地域別 - 産業予測 2025～2032年

糖尿病網膜症市場規模は2023年に95億米ドルと評価され、2024年の101億6,000万米ドルから2032年には173億2,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは6.9％で成長する見通しです。

糖尿病市場は、糖尿病有病率の上昇、人口の高齢化、糖尿病関連失明の発生率の増加などを背景に、大きく成長する見通しです。糖尿病に対する意識の高まりと革新的な製品のイントロダクションが、この動向をさらに加速させています。糖尿病は、膵臓のインスリン分泌不全から発症し、血糖値の上昇や網膜の毛細血管への潜在的な損傷を引き起こし、その結果が糖尿病網膜症です。これらのリスクを軽減するためには、早期の発見と介入、高度なツールを使用した継続的な自己モニタリング、生活習慣の改善が極めて重要です。チェック・アイの糖尿病網膜症スクリーニングのためのAI搭載プラットフォームなどの最近のイニシアチブは、早期発見を強化する努力を強調しています。さらに、ヘルスケア支出の増加と2050年までに高齢者人口が3倍になると予測されることは、市場力学を形成する上で不可欠です。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 規制分析
• 特許分析
• 技術分析

糖尿病網膜症市場規模：タイプ別& CAGR（2025-2032）

• 市場概要
• 非増殖性糖尿病網膜症
• 増殖性糖尿病網膜症

糖尿病網膜症市場規模：治療法別& CAGR（2025-2032）

• 市場概要
• 薬
• 機器使用
• 手術
• その他

糖尿病網膜症市場規模：診断別& CAGR（2025-2032）

• 市場概要
• フルオレセイン蛍光眼底造影検査
• 光干渉断層撮影
• その他

糖尿病網膜症市場規模：投与経路別& CAGR（2025-2032）

• 市場概要
• 経口
• 硝子体内注射
• 硝子体内インプラント
• 局所用点眼薬
• レーザー手術
• その他

糖尿病網膜症市場規模：エンドユーザー別& CAGR（2025-2032）

• 市場概要
• 病院
• 専門クリニック
• 在宅ケア
• その他

糖尿病網膜症市場規模：流通チャネル別& CAGR（2025-2032）

• 市場概要
• 病院薬局
• 小売薬局
• オンライン薬局
• その他

糖尿病網膜症市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Bayer AG（Germany）
• AbbVie Inc.（USA）
• Novartis AG（Switzerland）
• Oxurion NV（Belgium）
• Sirnaomics（China）
• Alimera Sciences（USA）
• Ampio Pharmaceuticals Inc.（USA）
• Kowa Company Ltd.（Japan）
• Genentech, Inc.（USA）
• Regeneron Pharmaceuticals Inc.（USA）
• Roche Holding AG（Switzerland）
• Allergan PLC（Ireland）
• Pfizer, Inc.（USA）
• Carl Zeiss Meditec AG（Germany）
• Topcon Corporation（Japan）
• Heidelberg Engineering GmbH（Germany）
• Optos PLC（UK）
• Canon Inc.（Japan）
• Nidek Co., Ltd.（Japan）
• Bausch+Lomb Incorporated（Canada）

結論と提言

Diabetic Retinopathy Market size was valued at USD 9.5 billion in 2023 and is poised to grow from USD 10.16 billion in 2024 to USD 17.32 billion by 2032, growing at a CAGR of 6.9% during the forecast period (2025-2032).

The diabetes market is poised for significant growth, driven by the escalating prevalence of diabetes, an aging population, and the increasing incidence of diabetes-related blindness. Heightened awareness about diabetes and the introduction of innovative products are further accelerating this trend. The condition arises from the pancreas's inability to produce insulin, leading to elevated blood sugar levels and potential damage to retinal blood capillaries, resulting in diabetic retinopathy. Early identification and intervention, continuous self-monitoring using advanced tools, and lifestyle changes are crucial for mitigating these risks. Recent initiatives, such as Check Eye's AI-powered platform for diabetic retinopathy screening, underscore efforts to enhance early detection. Additionally, rising healthcare spending and the projected tripling of the elderly population by 2050 will be vital in shaping market dynamics.

Top-down and bottom-up approaches were used to estimate and validate the size of the Diabetic Retinopathy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Diabetic Retinopathy Market Segments Analysis

Global Diabetic Retinopathy Market is segmented by Type, Treatment, Diagnosis, Route of Administration, End-Users, Distribution Channel and region. Based on Type, the market is segmented into Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy. Based on Treatment, the market is segmented into Medication, Through Device, Surgery and Others. Based on Diagnosis, the market is segmented into Fluorescein Angiography, Optical Coherence Tomography and Others. Based on Route of Administration, the market is segmented into Oral, Intravitreal Injections, Intravitreal Implants, Topical Eye Drops, Laser Surgery, Others. Based on End-Users, the market is segmented into Hospitals, Specialty Clinics, Homecare and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Diabetic Retinopathy Market

The diabetic retinopathy market is primarily driven by the rising global incidence of diabetes, which significantly heightens the prevalence of this common complication among diabetic patients. As more individuals are diagnosed with diabetes, the need for effective diagnostic tools and treatment solutions for diabetic retinopathy intensifies. This escalating diabetic population not only underscores the necessity for innovative therapies but also creates an expanding market for specialists and healthcare providers focused on managing and addressing the visual impairments associated with this condition. Consequently, the urgent demand for effective interventions stands as a vital propellant for the growth of the diabetic retinopathy market.

Restraints in the Diabetic Retinopathy Market

The diabetic retinopathy market faces several challenges that hinder its growth. A significant issue is the insufficient awareness among diabetic patients regarding the condition and the critical need for routine eye check-ups. Many individuals remain unaware of the risks associated with diabetic retinopathy, which can lead to severe vision impairment if not addressed promptly. Additionally, access to eye care services is often limited in remote or underserved regions, creating barriers to early detection and timely treatment. These factors collectively restrict the market's potential, underscoring the need for increased education and improved healthcare accessibility to mitigate these restraints.

Market Trends of the Diabetic Retinopathy Market

The diabetic retinopathy market is witnessing a notable trend towards early detection and intervention, driven by an increasing acknowledgment of the condition's progressive nature. Healthcare providers are investing in regular screening programs and community awareness campaigns to educate patients about the importance of timely diagnosis. Concurrently, advancements in imaging technologies, such as OCT and fundus photography, are enhancing the precision of early diagnosis. This proactive approach not only aims to reduce the incidence of severe vision loss but also to optimize treatment outcomes, thereby shaping the market dynamics and stimulating growth as both healthcare systems and patients prioritize preventive strategies.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Analysis
• Patent Analysis
• Technology Analysis

Global Diabetic Retinopathy Market Size by Type & CAGR (2025-2032)

• Market Overview
• Non-Proliferative Diabetic Retinopathy
• Proliferative Diabetic Retinopathy

Global Diabetic Retinopathy Market Size by Treatment & CAGR (2025-2032)

• Market Overview
• Medication
• Through Device
• Surgery
• Others

Global Diabetic Retinopathy Market Size by Diagnosis & CAGR (2025-2032)

• Market Overview
• Fluorescein Angiography
• Optical Coherence Tomography
• Others

Global Diabetic Retinopathy Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Intravitreal Injections
• Intravitreal Implants
• Topical Eye Drops
• Laser Surgery
• Others

Global Diabetic Retinopathy Market Size by End-Users & CAGR (2025-2032)

• Market Overview
• Hospitals
• Specialty Clinics
• Homecare
• Others

Global Diabetic Retinopathy Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Global Diabetic Retinopathy Market Size & CAGR (2025-2032)

• North America (Type, Treatment, Diagnosis, Route of Administration, End-Users, Distribution Channel)
  • US
  • Canada
• Europe (Type, Treatment, Diagnosis, Route of Administration, End-Users, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Treatment, Diagnosis, Route of Administration, End-Users, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Treatment, Diagnosis, Route of Administration, End-Users, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Treatment, Diagnosis, Route of Administration, End-Users, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oxurion NV (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sirnaomics (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alimera Sciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ampio Pharmaceuticals Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kowa Company Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genentech, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan PLC (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Carl Zeiss Meditec AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Topcon Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Heidelberg Engineering GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Optos PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Canon Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nidek Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch + Lomb Incorporated (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations